NASDAQ:PHAR Pharming Group - PHAR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. $13.45 +0.08 (+0.60%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$13.45▼$14.1650-Day Range$10.56▼$14.7852-Week Range$6.10▼$15.00Volume8,468 shsAverage Volume3,524 shsMarket Capitalization$878.02 millionP/E Ratio32.81Dividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Pharming Group (NASDAQ:PHAR) StockPharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Read More Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAR Stock News HeadlinesJanuary 19, 2023 | marketwatch.comHereditary Angioedema Treatment Market 2023 : Company Profile Analysis, Industry Segmentation, Opportunity Assessment and Forecast by 2028December 15, 2022 | markets.businessinsider.comPharming Reports Positive Interim Data From Study Of Leniolisib In Rare Primary ImmunodeficiencyFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 7, 2022 | seekingalpha.comPharming reports publishing of phase 3 data of rare immunodeficiency disorder drugDecember 7, 2022 | finanznachrichten.dePharming Group NV: Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's BloodDecember 7, 2022 | markets.businessinsider.comPharming : Positive Data From Phase 3 Study Of Leniolisib In Rare Primary Immunodeficiency PublishedDecember 7, 2022 | marketwatch.comPharming Group's Leniolisib Phase 3 Study Shows Positive DataDecember 1, 2022 | finance.yahoo.comHas Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! November 24, 2022 | finanznachrichten.dePharming Group N.V.: Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual MeetingNovember 3, 2022 | finanznachrichten.dePharming Group N.V.: Pharming to present at Stifel Healthcare ConferenceNovember 3, 2022 | finance.yahoo.comPharming to present at Jefferies Healthcare ConferenceNovember 2, 2022 | finance.yahoo.comPharming to present at Stifel Healthcare ConferenceOctober 28, 2022 | finance.yahoo.comPharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisibOctober 27, 2022 | finanznachrichten.dePharming Group N.V.: Pharming Group reports earnings for the first nine months of 2022October 27, 2022 | finance.yahoo.comPharming Group reports earnings for the first nine months of 2022October 18, 2022 | finance.yahoo.comAre Medical Stocks Lagging Lantheus (LNTH) This Year?October 12, 2022 | finanznachrichten.dePharming Group N.V.: Pharming Group Notice of Q3 ResultsOctober 11, 2022 | marketwatch.comPharming Group Submits Marketing Authorization Application for LeniolisibSeptember 28, 2022 | markets.businessinsider.comEuropean Shares Slump As Risk Appetite WanesSeptember 28, 2022 | nasdaq.comPharming: FDA Accepts Leniolisib NDA For Priority Review To Treat APDSSeptember 28, 2022 | finance.yahoo.comPharming Announces US FDA Acceptance for Priority Review of its New Drug Application for LeniolisibSeptember 7, 2022 | finance.yahoo.comCEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment ConferenceAugust 6, 2022 | seekingalpha.comPharming Group N.V.'s (PHGUF) CEO Sijmen de Vries on First Half 2022 Results - Earnings Call TranscriptAugust 1, 2022 | finance.yahoo.comPharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDSJuly 25, 2022 | finanznachrichten.dePharming Group N.V.: Pharming Group Notice of H1 2022 ResultsJuly 25, 2022 | finance.yahoo.comPharming Group Notice of H1 2022 ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAR Company Calendar Today2/02/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHAR CUSIPN/A CIK1828316 Webwww.pharming.com Phone31-71-524-7400FaxN/AEmployees262Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio32.81 Forward P/E Ratio269.00 P/E GrowthN/ANet Income$16 million Net Margins14.90% Pretax MarginN/A Return on Equity8.98% Return on Assets4.51% Debt Debt-to-Equity Ratio0.60 Current Ratio5.40 Quick Ratio4.68 Sales & Book Value Annual Sales$198.87 million Price / Sales4.42 Cash Flow$0.55 per share Price / Cash Flow24.36 Book Value$2.97 per share Price / Book4.53Miscellaneous Outstanding Shares65,280,000Free Float63,929,000Market Cap$878.02 million OptionableNot Optionable Beta0.22 Key ExecutivesDr. Sijmen de Vries M.B.A. (Age 63)M.D., MBA, Pres, CEO & Exec. Director Comp: $1.2MDr. Bruno M. L. Giannetti (Age 70)Consultant Mr. Jeroen Wakkerman (Age 53)Chief Financial Officer Ms. Mireille Sanders M.Sc. (Age 54)Chief Operations Officer Susanne EmbletonInvestor Relations Mang.Mr. Ruud Van Outersterp (Age 58)Chief Ethics & Compliance Officer Mr. Anurag Relan (Age 50)Chief Medical Officer Mr. Stephen Toor (Age 51)Chief Commercial Officer & GM of Americas More ExecutivesKey CompetitorsMirum PharmaceuticalsNASDAQ:MIRMRAPT TherapeuticsNASDAQ:RAPTInnovivaNASDAQ:INVAGemini TherapeuticsNASDAQ:GMTXBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInsiders & InstitutionsCowen Prime Advisors LLCBought 4,910 shares on 2/1/2023Ownership: 0.033%View All Institutional Transactions PHAR Stock - Frequently Asked Questions How have PHAR shares performed in 2023? Pharming Group's stock was trading at $11.03 at the beginning of 2023. Since then, PHAR stock has increased by 21.9% and is now trading at $13.45. View the best growth stocks for 2023 here. When is Pharming Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our PHAR earnings forecast. What is Pharming Group's stock symbol? Pharming Group trades on the NASDAQ under the ticker symbol "PHAR." Who are Pharming Group's major shareholders? Pharming Group's stock is owned by many different institutional and retail investors. Top institutional investors include Cowen Prime Advisors LLC (0.03%). How do I buy shares of Pharming Group? Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pharming Group's stock price today? One share of PHAR stock can currently be purchased for approximately $13.45. How much money does Pharming Group make? Pharming Group (NASDAQ:PHAR) has a market capitalization of $878.02 million and generates $198.87 million in revenue each year. The company earns $16 million in net income (profit) each year or $0.41 on an earnings per share basis. How many employees does Pharming Group have? The company employs 262 workers across the globe. How can I contact Pharming Group? Pharming Group's mailing address is DARWINWEG 24, LEIDEN P7, 2333 CR. The official website for the company is www.pharming.com. The company can be reached via phone at 31-71-524-7400 or via email at investor@pharming.com. This page (NASDAQ:PHAR) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.